Solara Active Pharma Sciences Limited — Others, 15-05-2025: Change in Auditors

Solara Active Pharma Sciences has announced a board meeting outcome approving the financial results for the quarter and half-year. Q4 revenue stood at ₹279 Cr, with FY25 revenue at ₹1,292 Cr, largely flat year-on-year. Strong margin expansion drove gross margin up to 51.5% from 37.8%, and EBITDA rose to ₹214 Cr (16.5%) from a prior-year loss. This improvement came from increased regulated market sales, cost controls, and operational efficiencies. Net debt declined by ₹223 Cr to ₹776 Cr. The company appointed a new Company Secretary, revised key policies, and made auditor changes. CRAMS and Polymers businesses will be demerged into a separate listed entity to strengthen the balance sheet and unlock value. Solara is focused on profitability, debt reduction, and margin-driven growth ahead.